Make faster, better drug development decisions
Bispecific antibodies are enjoying a renaissance owing to developments in T-cell engaging, checkpoint, and multi-specific ADC approaches. Whether they are rivaling CAR-T/TCR therapies by targeting CD3, providing checkpoint combinations in one molecule, or engaging novel targets, bispecifics are offering novel, diverse and promising performance. The challenge of tracking and searching the trial and drug landscape owes to the diverse synonyms and taxonomies involved. Beacon has the solution.
Beacon Bispecific
Maximize Your Data With the Most Complete Trial, Drug, and Commercial Database for Bispecifics
What We Cover
This database solution is manually curated by sector-specific scientists and includes clinical trial and drug records for preclinical, active, approved, and discontinued antibody-based drugs that are designed to bind to two or more target antigens. We also cover:
- Whole Antibodies
- Antibody Fragments
- Augmented Antibodies
- Bispecific Fusion Proteins
Commercial intelligence data expansion: Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more by downloading the factsheet.
How Beacon Helps
Here are a few example use cases that have benefitted our clients in accelerating their Bispecific development programs:
- Benchmark drug development and clinical trial strategies against competitors.
- Getting an in-depth competitive landscape overview of the competitors and their assets in the clinic.
- Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on phase distribution, targets, disease indication, drug discontinuations and much more.
- Identify new players and new assets entering the clinic and monitor their progress.
How Beacon Bispecific Works
Search the clinical trial and drug landscape by multiple targets, scaffold and over 80 different bispecific formats instantaneously, or extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the bispecific space.
How We Source the Data for Bispecific and Multispecific Therapies
We house all publicly available sources of data updated with 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
- Patents
Related Content
H1 2024 Bispecific Landscape Review
Unlocking the Potential of Bispecific ADCs
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
What Our Customers Say
"I’ve rarely seen such dedication from a service provider in understanding and responding to our needs"
Competitive Intelligence Manager
Bispecific Drug Developer
Our Bispecific Expert
Flavio Lima Bianchi is the lead research analyst for bispecific-related drugs and trials in the Beacon team.
Sign up to our weekly newsletter with the latest bispecific landscape insights and updates with data from Beacon Bispecific.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Beacon Cell Therapy covers genetically and non-genetically engineered allogeneic and autologous cell-based therapies across all disease indications
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any Questions? Contact Us
To learn how Beacon Bispecific can align, optimize, and maximize your trial, drug, and commercial intelligence, get in touch with our sales team.
About Beacon
Beacon is a world-leading data analysis subscription platform for drug, trial, and commercial intelligence. With unrivaled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information that gives you the confidence to progress your targeted drug therapies to patients.
